---
title: "Egetis Therapeutics Highlights Rare Disease Focus and Commercialization Plans in 2025 Annual Report"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280335741.md"
description: "Egetis Therapeutics Highlights Rare Disease Focus and Commercialization Plans in 2025 Annual Report"
datetime: "2026-03-24T14:35:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280335741.md)
  - [en](https://longbridge.com/en/news/280335741.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280335741.md)
generator: "portal-rs"
---

# Egetis Therapeutics Highlights Rare Disease Focus and Commercialization Plans in 2025 Annual Report

Egetis Therapeutics Highlights Rare Disease Focus and Commercialization Plans in 2025 Annual Report

### Related Stocks

- [ATXS.US](https://longbridge.com/en/quote/ATXS.US.md)

## Related News & Research

- [Percheron Therapeutics Corrects Auditor Report Omission in FY2026 Annual Filing](https://longbridge.com/en/news/296318843.md)
- [BioMarin to acquire Alesta Therapeutics for $275 million for potential rare bone disease treatment](https://longbridge.com/en/news/296376333.md)
- [One Platform, Every Ailment: Hinge Health's Gamble](https://longbridge.com/en/news/296483875.md)
- [Rein Therapeutics says FDA grants Fast Track status to LTI-03 in idiopathic pulmonary fibrosis](https://longbridge.com/en/news/296487342.md)
- [BrainStorm Cell Therapeutics GAAP EPS of -$0.35](https://longbridge.com/en/news/296069988.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**